Brands
Fire-Boltt signs MS Dhoni as its new brand ambassador
Mumbai: Fire-Boltt has appointed Mahendra Singh Dhoni as its new brand ambassador. Dhoni is the latest addition to the brand’s highly aggressive marketing & endorsement plans for India.
The legendary cricketer will be the leading face of the brand and take part in a variety of marketing, advertising, and endorsement activities for Fire-Boltt, which has once again taken the top spot in the Indian smartwatch market with a market share of 28 per cent.
Dhoni is known for his reliability, and the partnership will not only allow the brand to aggressively expand its footprints across the country but will also strengthen its identity as the most reliable smartwatch brand in India.
The association with MS Dhoni will further help Fire-Boltt reach a wider audience, not only in India but across the globe. This partnership will play a crucial role for the brand as the smartwatch market is growing at a rapid pace, and the brand aims to set a benchmark in the smartwatch industry in the near future.
Talking about his association with the brand and the smartwatch, Mahendra Singh Dhoni said, “Fitness plays an important role in my life. Being an athlete, consistency is important. Fire-Boltt’s range of smartwatches assists people in performing the right amount of workouts. I’m glad to be associated with a brand that has a global appeal.”
Commenting on this partnership, Fire-Boltt founder and CEO Arnav Kishore asserted, “We are extremely passionate about the addition of MS Dhoni to our group of inspiring ambassadors; he is a natural fit for the brand. The impeccable personality of MS Dhoni and his continuous fame marries well with our vision to carve a niche for ourselves in the fit-tech space. MS Dhoni is one of the most respected cricketers in the world, and he remains an idol for aspiring cricketers across the globe. The association with this iconic wicketkeeper, captain, batsman, or one may say a living legend reflects our unwavering commitment to offering people the best solution to their smartwatch woes.”
“The ethos of Fire-Boltt to foster a holistic experience for each & every customer has been deeply imbibed in all the initiatives that we undertake here, and MS Dhoni embodies Fire-Boltt’s fitness heritage seamlessly. From the factory level to the top management, true & cohesive efforts are reflected in all of our products, communication, branding, and customer relations. With this association, we wish to accentuate our capabilities and become a household name just like Mahendra Singh Dhoni,” added Fire-Boltt co-founder Aayushi Kishore.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
